Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TCR alpha/beta/CD19-depleted allogeneic hematopoietic progenitor cells

A preparation of hematopoietic progenitor cells (HPCs) from a haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that can potentially be used for immune reconstitution purposes. The TCR alpha/beta/CD19-depleted HPCs contain high amounts of natural killer (NK) cells, gamma/delta T cells, CD34+ stem cells, monocytes, and dendritic cells (DCs), while devoid of alpha/beta T cells and CD19-positive B cells. The TCR alpha/beta/CD19-depleted HPCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, rapid immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic alpha, beta TCR/CD19-depleted HPCs
allogeneic TCRab/CD19-depleted hematopoietic stem cells
TCR alpha/beta/CD19-depleted HPCs
TCR alpha/beta+/CD19+ depleted ematopoietic progenitor cells
TCR alpha/beta+/CD19+ depleted HPCs
TCRab-/CD19-depleted allogeneic hematopoietic progenitor cells
TCRab-/CD19-depleted hematopoietic progenitor cells
TCRab+/CD19+-depleted haploidentical donor HPCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search